"The Italian pharmaceutical industry is unique in Europe, consisting of approximately 40% Italian-owned companies and 60% internationally. And they all—large, medium, and small—best embody the essence of Made in Italy". This is indicated in the summary of key numbers for the pharmaceutical business in 2025, which was released during the 2026 Farmindustria Assembly. With €74 billion in production, Italy ranks among the leading pharmaceutical producers in the European Union alongside Germany and France. The pharmaceutical industry contributes 2% of GDP, both directly and through related industries. It is the most productive and competitive (three times the average) and has experienced the greatest productivity growth over the past two decades (Istat). Also, in comparison to large EU countries, the Italian pharmaceutical industry is the most productive (+5%). Italy has invested €4.4 billion (€1.9 billion in production and €2.5 billion in R&D), a 9% increase in 2025 and a 43% increase over the past five years. The pharmaceutical industry is the second largest manufacturing sector in terms of exports, following mechanical engineering, with a total of €69.2 billion in 2025. It is the leading manufacturing sector in terms of export growth, with a 28.5 percent increase in 2025 and a 248% increase over the past decade (2015-2025). Pharmaceutical exports have grown at a rate that exceeds that of other major EU states and the EU average over the past decade (+148%). Italy ranked sixth in the world for overall pharmaceutical exports in 2025, with a 7.7% share, up from 4% in 2015; however, it is in second place with a 10% share of packaged drugs, after Germany (13%).